In the current study, we investigate the enhanced tumor growth inhibition and related antitumor immune mechanisms of anti-PD-1 antibody in combination with a novel next-generation ASO of TGF-β2 (ngTASO) for the treatment of melanoma. Here, TGFB2 is linked to neoplasm.